Dual pathway inhibition (DPI) with low-dose rivaroxaban and aspirin in patients with
coronary artery disease (CAD) and/or peripheral artery disease (PAD) reduces the …

COMPASS study demonstrated efficacy of dual pathway inhibition with 2.5 mg twice daily
rivaroxaban and aspirin in patients with polyvascular disease (coronary artery disease …

Aim Inhibition of thrombin-mediated signaling processes using a vascular dose of
rivaroxaban in adjunct to antiplatelet therapy, known as dual-pathway inhibition (DPI) …

Atherosclerotic cardiovascular disease (ASCVD), which includes coronary artery disease
(CAD), cerebrovascular disease, and peripheral arterial disease (PAD) is associated with …

Despite available effective guideline-based preventive therapies, patients with vascular
diseases remain at high-risk of recurrent ischaemic events. Novel therapeutic strategies are …

Objective Dual pathway inhibition (DPI) by combining acetylsalicylic acid (ASA) with low-
dose rivaroxaban has been shown to reduce cardiovascular events in patients with …

Aims To determine the characteristics of patients with coronary artery disease (CAD),
peripheral artery disease (PAD), or both, initiating dual pathway inhibition (DPI) using …

Aims Guidelines recommend extended dual pathway inhibition (DPI) with aspirin and
rivaroxaban in patients with chronic coronary syndrome (CCS) at high ischaemic risk. The …

Introduction The persistence of elevated rates of ischemic recurrences despite the use of
antiplatelet therapy among patients with atherosclerotic disease together with the …

Despite advances in secondary prevention strategies in patients with cardiovascular
disease, the residual risk of recurrent atherothrombotic events remains high. Dual …